Ionis Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. 

CEO
Brett P. Monia
CEOBrett P. Monia
Employees
1,069
Employees1,069
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
1989
Founded1989
Employees
1,069
Employees1,069

IONS Key Statistics

Market cap
13.26B
Market cap13.26B
Price-Earnings ratio
-47.79
Price-Earnings ratio-47.79
Dividend yield
Dividend yield
Average volume
2.66M
Average volume2.66M
High today
$82.19
High today$82.19
Low today
$78.89
Low today$78.89
Open price
$79.62
Open price$79.62
Volume
3.66M
Volume3.66M
52 Week high
$86.15
52 Week high$86.15
52 Week low
$23.95
52 Week low$23.95

Stock Snapshot

As of today, Ionis Pharmaceuticals(IONS) shares are valued at $81.79. The company's market cap stands at 13.26B, with a P/E ratio of -47.79.

On 2026-01-22, Ionis Pharmaceuticals(IONS) stock moved within a range of $78.89 to $82.19. With shares now at $81.79, the stock is trading +3.7% above its intraday low and -0.5% below the session's peak.

Trading volume for Ionis Pharmaceuticals(IONS) stock has reached 3.66M, versus its average volume of 2.66M.

The stock's 52-week range extends from a low of $23.95 to a high of $86.15.

The stock's 52-week range extends from a low of $23.95 to a high of $86.15.

IONS News

Simply Wall St 1d
Assessing Ionis Pharmaceuticals Valuation After TRYNGOLZA Sales Beat And Pipeline Progress

Advertisement What Ionis’ latest update means for shareholders Ionis Pharmaceuticals (IONS) kicked off 2026 by spotlighting 2025 milestones, including US$105...

Assessing Ionis Pharmaceuticals Valuation After TRYNGOLZA Sales Beat And Pipeline Progress
TipRanks 2d
Ionis Pharmaceuticals announces European Commission approval for Dawnzera

Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that the European Commission has approved Dawnzera in the European Union for the routine preven...

Analyst ratings

71%

of 24 ratings
Buy
70.8%
Hold
29.2%
Sell
0%

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.